GC GC Holdings
A Game Changer in Global Total Health Care
The GC Group leading the digital healthcare industry
based on its strong pharmaceutical foundation.
more
The GC Group leading the digital healthcare industry
based on its strong pharmaceutical foundation.
Dreaming of a world where humanity no longer must suffer from disease and illnesses,
the GC Group is taking large strides as a global leader in the health industry rising above
and beyond the scope of a domestic health care company.
With a total of 40 affiliates at home and abroad (25 domestic, 15 overseas), the GC
Group delegates the management of the entire Group operations, including strategic
direction, new business creation, and portfolio management to the GC Holdings
company, while each affiliate takes charge of the manufacturing and sales of special
medicine and digital healthcare business.
GC Group is a biotech-based global total healthcare group that encompasses products
and services such as disease prevention, diagnosis, treatment, medical devices, and
healthcare.
the GC Group is taking large strides as a global leader in the health industry rising above
and beyond the scope of a domestic health care company.
With a total of 40 affiliates at home and abroad (25 domestic, 15 overseas), the GC
Group delegates the management of the entire Group operations, including strategic
direction, new business creation, and portfolio management to the GC Holdings
company, while each affiliate takes charge of the manufacturing and sales of special
medicine and digital healthcare business.
GC Group is a biotech-based global total healthcare group that encompasses products
and services such as disease prevention, diagnosis, treatment, medical devices, and
healthcare.
Shortcut
It may be the tougher road to take, but a necessary one.
GC Biopharma is a company that is relentless in its challenge to find breakthroughs in essential new drug developments. To this end, we were able to achieve outstanding results in vaccines, rare disease treatments, and blood derivatives.
1. Developed the world's first hemorragic fever vaccine, Korea's first flu vaccine
2. Second company in the world to develop cure for Hunter syndrome and varicella vaccine
3. Third company in the world to develop the hepatitis b vaccine and third-generation recombinant hemophilia treatment.
4. Fourth company in the world to pass WHO prequalification for flu vaccine
"GC Biopharma vows to be your loyal partner and leader in the global health industry to ensure the prevention, diagnosis, and treatment of all diseases."
"Going beyond our borders in Korea, GC Biopharma will support the health industry from various angles so that people around the world may enjoy healthier and happier lives."
GC Biopharma is a company that is relentless in its challenge to find breakthroughs in essential new drug developments. To this end, we were able to achieve outstanding results in vaccines, rare disease treatments, and blood derivatives.
1. Developed the world's first hemorragic fever vaccine, Korea's first flu vaccine
2. Second company in the world to develop cure for Hunter syndrome and varicella vaccine
3. Third company in the world to develop the hepatitis b vaccine and third-generation recombinant hemophilia treatment.
4. Fourth company in the world to pass WHO prequalification for flu vaccine
"GC Biopharma vows to be your loyal partner and leader in the global health industry to ensure the prevention, diagnosis, and treatment of all diseases."
"Going beyond our borders in Korea, GC Biopharma will support the health industry from various angles so that people around the world may enjoy healthier and happier lives."
Through GC Cell's unique next-generation cell and gene therapy platform technology, the company is
researching and developing competitive cell gene therapy that can ensure safety and effectiveness in
the entire process from basic research to quality/production/clinical for the base technology.
Based on years of accumulated experience in cell therapy production and clinical trials, the company provides mass production of immuno-cancer drugs and industry-leading customized CDMO services from Cell Center, which is the largest cell therapy production facility in Korea.
GC Cell provides international standard test quality and customized total-solution for sales marketing, transportation network, and customer support management from the time of sample collection at hospitals nationwide to the provision of test results.
Through a specialized logistics system, bioengineering products are accurately and safely transported, and GC Medical Foundation, the nation's top clinical examination medical institution, provides quick and accurate results with international quality.
Based on years of accumulated experience in cell therapy production and clinical trials, the company provides mass production of immuno-cancer drugs and industry-leading customized CDMO services from Cell Center, which is the largest cell therapy production facility in Korea.
GC Cell provides international standard test quality and customized total-solution for sales marketing, transportation network, and customer support management from the time of sample collection at hospitals nationwide to the provision of test results.
Through a specialized logistics system, bioengineering products are accurately and safely transported, and GC Medical Foundation, the nation's top clinical examination medical institution, provides quick and accurate results with international quality.
GC EM is the total bioengineering & comprehensive construction company that has the largest
performance in GMP & Bio Lab Engineering field in Korea.
The company is creating the value that customers need with a commitment to contribute to the health of the people by constructing excellent drug manufacturing facilities and research facilities, which are infrastructure for national health.
GC EM has accumulated the highest level of bio/GMP engineering portfolio and expertise in Korea as it systemically provides One-Stop Service ranging from [Design - Construction - Validation - Maintenance] as a bioengineering Total Solution Partner, and has the highest competitive edge in the field.
Being recognized for its excellent quality and technological value, it successfully carried out the construction project of the Microbiological Validation Support Center and the Public Vaccine Development Support Center as a contractor for the vaccine global industrialization infrastructure project, a national institutional project. The company built BL4 research facility for the Korea Centers for Disease Control and Prevention, which is the first and only in Korea to have the highest bio-safety rating.
For private industry, the company has built the GC Ochang Plant•W&FF, the nation's largest GMP plant, and the Hwasun Plant, the nation's only influenza production facility, and it also built a research facility called SL Bigen Industrial-Academic Cooperation Hall, which studies cell therapy agents with high-tech regenerative bioagent.
It has a large portfolio of bioengineering industrial facilities and plays a pivotal role in the industry.
GC EM is not satisfied just with the nation's best technology and strives for more.
Through overseas technology research and active investment in training bio-specialized engineers for all employees, it is growing as a global leader in the bio-engineering industry.
The company is creating the value that customers need with a commitment to contribute to the health of the people by constructing excellent drug manufacturing facilities and research facilities, which are infrastructure for national health.
GC EM has accumulated the highest level of bio/GMP engineering portfolio and expertise in Korea as it systemically provides One-Stop Service ranging from [Design - Construction - Validation - Maintenance] as a bioengineering Total Solution Partner, and has the highest competitive edge in the field.
Being recognized for its excellent quality and technological value, it successfully carried out the construction project of the Microbiological Validation Support Center and the Public Vaccine Development Support Center as a contractor for the vaccine global industrialization infrastructure project, a national institutional project. The company built BL4 research facility for the Korea Centers for Disease Control and Prevention, which is the first and only in Korea to have the highest bio-safety rating.
For private industry, the company has built the GC Ochang Plant•W&FF, the nation's largest GMP plant, and the Hwasun Plant, the nation's only influenza production facility, and it also built a research facility called SL Bigen Industrial-Academic Cooperation Hall, which studies cell therapy agents with high-tech regenerative bioagent.
It has a large portfolio of bioengineering industrial facilities and plays a pivotal role in the industry.
GC EM is not satisfied just with the nation's best technology and strives for more.
Through overseas technology research and active investment in training bio-specialized engineers for all employees, it is growing as a global leader in the bio-engineering industry.
The company established the nation's highest level of blocking and quarantine system, operates a
production plant that produces fertile eggs according to thorough quality control standards, and
operates hatching plants that hatch fertile eggs suitable for vaccine production,
It contributes to the growth of the flu vaccine by providing high-quality Eggs for vaccines stably
It contributes to the growth of the flu vaccine by providing high-quality Eggs for vaccines stably
The institute made its appearance in 1984 with the fund from GC's third successful hepatitis B
vaccine.
Mogam Institute was established with the goal of creating a stable and continuous research environment by promoting social contribution and profit creation through the development of life science and technology and reinvesting it in research and development. This private research institution is the first non-profit research foundation established with approval from the Ministry of Science and ICT in Korea.
The main areas of research are cancer, vaccines, rare diseases, and metabolic diseases, and it is developing medicines using artificial intelligence technology.
Mogam Institute was established with the goal of creating a stable and continuous research environment by promoting social contribution and profit creation through the development of life science and technology and reinvesting it in research and development. This private research institution is the first non-profit research foundation established with approval from the Ministry of Science and ICT in Korea.
The main areas of research are cancer, vaccines, rare diseases, and metabolic diseases, and it is developing medicines using artificial intelligence technology.